Clinical Trials · NCT07650240
Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Mayo Clinic
- Enrollment
- 202
- Start date
- Aug 2026
- Locations
- 1 site, United States
- Primary endpoint
- Radiographic progression free survival (rPFS)